Ocular Toxicity of Targeted Anticancer Agents

Fortes, Blake H; Tailor, Prashant D; Dalvin, Lauren A

doi:10.1007/s40265-021-01507-z

Cited by 36 publications

(39 citation statements)

References 389 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MEKi-associated retinopathy (MEKAR) was recently described separately from CSCR [ 6 ]. MEKAR is also characterized by a serous (fluid-filled) retinal detachment without choroidal involvement, secondary to MEKi therapy [ 13 , 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report

et al. 2022

View full text Add to dashboard Cite

Emerging anticancer agents such as the pan-FGFR Inhibitor have achieved remarkable improvements in the survival of patients with metastatic malignancies. Nevertheless they are still associated with specific ophthalmic toxicities. Understanding their pathophysiology can lead us to better clinical practice of life-threatening and vision-threatening circumstances. To investigate choroidal alterations as a potential pathophysiological mechanism of a serous detachment in bilateral pan-FGFR Inhibitor-Associated Retinopathy (FGFRAR), the morphology of the choroid and choriocapillaris were assessed. The choroidal thickness (ChT) and choriocapillaris flow void were measured by macular optical coherence tomography (OCT) and angiography (OCT-A), respectively. Data were collected at the baseline, then at one-month and two-months follow-ups after starting erdafitinib, in a single case of pulmonary angiosarcoma. Choroidal and choriocapillaris morphology showed stable ChT and choriocapillaris flow void at FGFRAR onset and relapse. To the best of our knowledge, this is the first analyzed case reported with flow-void OCT-angiography. Considering these results, FGFRAR in this patient does not seem to match the pachychoroid spectrum disorder definition; rather, an intracellular mechanism based on intracellular transduction pathways may be at work.

show abstract

Section: Discussionmentioning

confidence: 99%

Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite not having research data to support this, it was postulated that the concentration of the daily oral anti-VEGF drug is higher in the uvea than that of a single vitreous injection of the same drug. The medication is found in a much higher concentration in the uvea over a continuous period and remains in the pigmented uvea for several weeks or months [8,9].…”

Section: Discussionmentioning

confidence: 99%

Corneo-Uveal-Retinal Adverse Effects after Single Course of Targeted Anti-Cancer Therapy: Case Report and Review of Literature

Fattah¹,

Al-Anazi²,

Kayali³

et al. 2021

Act Sci Oph

View full text Add to dashboard Cite

Oral anti vascular endothelial growth factors therapeutic agents have been evolving rapidly over the last past decades and became one of the great contributors to advancement of cancer therapy and increasing survival rate of the treated patients.Sorafenib is FDA approved medications for the treatment of solid tumors.In this article, we reported the clinical features of the first Saudi patient presenting with corneo-uveal retinal adverse effects with subsequent bilateral irreversible blindness.

show abstract

“…Finally, consider Vogt-Koyanagi-Harada-like syndrome if intraocular inflammation occurs in tandem with other autoimmune adverse reactions, as this may require the use of systemic steroids to minimize the risk of vision loss. 2 …”

Section: Growth Factor Modulatorsmentioning

confidence: 99%

“…Biologics are involved in ubiquitous processes throughout the body and can have seemingly unrelated adverse effects. Previous reviews have discussed ocular adverse effects of biologics that were specific to oncology, 1 , 2 neuro-ophthalmology, 3 or the retina. 4 To our knowledge, this is the first study to review ocular adverse effects of currently available biological medication listed in the FDA’s Purple Book 5 according to our criteria of inclusion.…”

Section: Introductionmentioning

confidence: 99%

Ocular adverse effects of therapeutic biologics

et al. 2022

View full text Add to dashboard Cite

Biological drugs, termed biologics, are medications that contain or are derived from a living organism (human, animal, or microorganism). With new biological agents being approved by the Food and Drug Administration (FDA) every year, clinicians need to know potential ocular adverse effects that are associated with these drugs. This review provides an overview of ocular adverse effects of biological medications used to treat both ophthalmic and non-ophthalmic diseases. We searched PubMed for relevant case reports, case series, reviews, and clinical trials reporting ocular adverse effects caused by biologics. This review was conducted in June 2021 and investigated the drugs listed in the most updated (April 2021) FDA Purple Book Database of Licensed Biological Products. This review focuses on monoclonal antibodies, interleukins, and receptor fusion proteins. We explore ocular side effects of 33 biological drugs, stating whether they are frequent, common, or rare.

show abstract

Ocular Toxicity of Targeted Anticancer Agents

Cited by 36 publications

References 389 publications

Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report

Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report

Corneo-Uveal-Retinal Adverse Effects after Single Course of Targeted Anti-Cancer Therapy: Case Report and Review of Literature

Ocular adverse effects of therapeutic biologics

Contact Info

Product

Resources

About